Emergence of vancomycin-intermediate Staphylococcus aureus in a Belgian hospital: microbiological and clinical features.
In 1999, all clinical Staphylococcus aureus isolates from patients admitted to a Belgian University hospital were tested for decreased vancomycin susceptibility. Three vancomycin-intermediate Staphylococcus aureus (VISA) and four hetero-VISA strains were detected among 2145 isolates tested. They emerged from strains that belonged to locally endemic methicillin-resistant S. aureus (MRSA) genotypes in three patients who had received repeated courses of vancomycin therapy. A cystic fibrosis patient with MRSA/VISA-associated broncho-pulmonary exacerbation was successfully treated by continuous vancomycin infusion plus fusidic acid followed by oral minocycline-fusidic acid. Two other patients had VISA recovered from specimens of undetermined clinical significance. Emergence of VISA variants of endemic MRSA strains in Belgium warrants active microbiological surveillance and careful monitoring of vancomycin therapy. Therapy with high-dose vancomycin administered by continuous infusion in combination with other antimicrobials may be a therapeutic option worth investigating for VISA infection.
Service de Microbiologie, Hôpital Erasme, Université Libre de Bruxelles, 808 route de Lennik, 1070 Brussels, Belgium. odenis@ulb.ac.be
Olivier
O
Denis
Claire
C
Nonhoff
Baudouin
B
Byl
Christiane
C
Knoop
Sophie
S
Bobin-Dubreux
Marc J
MJ
Struelens
D000293:Adolescent; D001530:Belgium / Q000453:epidemiology; D003428:Cross Infection / Q000382:microbiology; D004359:Drug Therapy, Combination; D005260:Female; D005672:Fusidic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D005838:Genotype; D006785:Hospitals, University; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D016106:Methicillin Resistance; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D013203:Staphylococcal Infections / Q000188:drug therapy / Q000453:epidemiology* / Q000382:microbiology; D013211:Staphylococcus aureus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification*; D016896:Treatment Outcome; D014640:Vancomycin / Q000008:administration & dosage / Q000627:therapeutic use*; D020713:Vancomycin Resistance / Q000235:genetics
D005672:Fusidic Acid; D014640:Vancomycin